Join the club for FREE to access the whole archive and other member benefits.

Steven Braithwaite

CSO at Alkahest, Inc.

Steven has extensive experience in therapeutic development in the biotechnology and pharmaceutical industries. He previously led research at Circuit Therapeutics, drug discovery at Signum Biosciences, headed the cellular neurodegeneration group at Wyeth/Pfizer, and was a program leader at AGY Therapeutics. In these roles he has led both small molecule and biological research and development programs across a diverse range of indications in the field of neuroscience. Steven is a graduate of the University of Cambridge, UK, received his PhD from the University of Bristol, UK and performed postdoctoral work at Stanford University. He also serves as an Adjunct Assistant Professor of Neurology at Rutgers University.

Visit website:


See also: Company Alkahest - Biotechnology company focused on treating neurodegenerative and other age-related diseases

Details last updated 24-Jan-2020

Steven Braithwaite is also referenced in the following:

Longevity Leaders World Congress 2021

04-May-2021 to 07-May-2021

The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).

Steven Braithwaite News

Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year


Longevity Leaders' latest report on how longevity is disrupting the world

Longevity Leaders (LSX) - 01-Jan-2020

An interesting collection of interviews and white-papers with industry leaders